A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE - Regional Cancer Care Associates LLC

Clinical Trials

A PHASE 2, INTERNATIONAL, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-486 (ORAL AZACITIDINE) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR INJECTIONOR DECITABINE

Type of Cancer
Leukemia
Locations
Hackensack
Sponsor
Celgene
Protocol Number
CC-486-MDS-006
Cancer Diagnosis
To Learn More Call
201-510-0910